TAIMEI TECH (Zhejiang Taimei Medical Technology Co., Ltd.) disclosed a further on-market repurchase of 20,000 H shares on 28 September 2026 under its existing share-buyback mandate.
The shares were bought on the Hong Kong Stock Exchange at prices ranging from HKD 4.63 to HKD 4.995, with a volume-weighted average outlay of HKD 94,375. Following the transaction, the company’s treasury share balance rose to 7.30 million, while the number of issued shares outstanding slipped to 193.29 million—a marginal 0.01% reduction from the previous level.
Since receiving shareholder approval on 23 June 2026 to repurchase up to 20.02 million shares, TAIMEI TECH has accumulated 6.88 million repurchased shares, equivalent to 3.44% of the share count in place at the mandate date.
In line with Hong Kong listing rules, the company is subject to a moratorium on new share issues or treasury-share disposals until 28 October 2026.